Harbor Capital Advisors’s Maravai LifeSciences MRVI Stock Holding History

Harbor Capital Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9K	Buy	3,060 +1,150	+60%	+$3.9K	﹤0.01%	1012
2025 Q4	$6K	Sell	1,910 -33	-2%	-$111	﹤0.01%	1100
2025 Q3	$6K	Sell	1,943 -2,114	-52%	-$5.4K	﹤0.01%	1118
2025 Q2	$10K	Buy	4,057 +951	+31%	+$2K	﹤0.01%	976
2025 Q1	$7K	Buy	3,106 +880	+40%	+$3.48K	﹤0.01%	1085
2024 Q4	$12K	Buy	2,226 +261	+13%	+$1.68K	﹤0.01%	916
2024 Q3	$16K	Buy	+1,965	New	+$17K	﹤0.01%	858
2023 Q3	–	Sell	-3,807	Closed	-$47.3K	–	575
2023 Q2	$47.3K	Buy	+3,807	New	+$51.4K	0.01%	501

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harbor Capital Advisors's MRVI Position: Q1 2026 in Review

Harbor Capital Advisors increased its Maravai LifeSciences (MRVI) stake by 60% in Q1 2026, buying an estimated $3.9K and bringing the position to 3,060 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Harbor Capital Advisors first reported a position in MRVI in Q2 2023 and has held it in 8 quarters since. The position peaked at $47.3K in Q2 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Harbor Capital Advisors held 3,060 shares of Maravai LifeSciences worth $9K as of Q1 2026.
Harbor Capital Advisors bought 1,150 Maravai LifeSciences shares in Q1 2026, an estimated $3.9K.
Maravai LifeSciences made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #1012 holding.
Harbor Capital Advisors first reported a position in Maravai LifeSciences in Q2 2023 and has held it in 8 quarters since.
Harbor Capital Advisors's Maravai LifeSciences position peaked at $47.3K in Q2 2023.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.